Gain of chromosome 8q is associated with metastases and poor survival of patients with clear cell renal cell carcinoma

Cancer

Volumn 118, Issue 23, 2012, Pages 5777-5782

  Klatte, Tobias ^a   Kroeger, Nils ^a   Rampersaud, Edward N ^a   Birkhäuser, Frédéric D ^a   Logan, Joshua E ^a   Sonn, Geoffrey ^a   Riss, Joseph ^a   Rao, P Nagesh ^a   Kabbinavar, Fairooz F ^a   Belldegrun, Arie S ^a   Pantuck, Allan J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

8q; c myc; concordance; kidney cancer; mitogen activated protein kinase; prognosis; sorafenib

Indexed keywords

MYC PROTEIN;

ADULT; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CHROMOSOME; CHROMOSOME 8Q; CHROMOSOME GAIN; COHORT ANALYSIS; CONTROLLED STUDY; CYTOGENETICS; DISEASE ASSOCIATION; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS; FEMALE; HIGH RISK PATIENT; HUMAN; KARYOTYPE; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEPHRECTOMY; ONCOGENE C MYC; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TUMOR VOLUME;

CARCINOMA, RENAL CELL; CHROMOSOMES, HUMAN, PAIR 8; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENES, MYC; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED;

EID: 84869495984     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27607     Document Type: Article

References (31)

1. Klatte T, Rao PN, de Martino M, et al. Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol. 2009; 27: 746-753.
2. La Rochelle J, Klatte T, Dastane A, et al. Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma. Cancer. 2010; 116: 4696-4702.
3. Patard JJ, Fergelot P, Karakiewicz PI, et al. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer. 2008; 123: 395-400. (Pubitemid 351842025)
4. Pei J, Feder MM, Al-Saleem T, et al. Combined classical cytogenetics and microarray-based genomic copy number analysis reveal frequent 3;5 rearrangements in clear cell renal cell carcinoma. Genes Chromosomes Cancer. 2010; 49: 610-619.
5. Rosenwald IB,. The role of translation in neoplastic transformation from a pathologist's point of view. Oncogene. 2004; 23: 3230-3247. (Pubitemid 38638835)
6. Vita M, Henriksson M,. The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol. 2006; 16: 318-330. (Pubitemid 44311040)
7. Tang SW, Chang WH, Su YC, et al. MYC pathway is activated in clear cell renal cell carcinoma and essential for proliferation of clear cell renal cell carcinoma cells. Cancer Lett. 2009; 273: 35-43.
8. Chang YS, Adnane J, Trail PA, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol. 2007; 59: 561-574. (Pubitemid 46295136)
9. Robson S, Pelengaris S, Khan M,. c-Myc and downstream targets in the pathogenesis and treatment of cancer. Recent Pat Anticancer Drug Discov. 2006; 1: 305-326.
10. Ribeiro FR, Jeronimo C, Henrique R, et al. 8q gain is an independent predictor of poor survival in diagnostic needle biopsies from prostate cancer suspects. Clin Cancer Res. 2006; 12: 3961-3970. (Pubitemid 44078081)
11. El Gammal AT, Bruchmann M, Zustin J, et al. Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer. Clin Cancer Res. 2010; 16: 56-64.
12. Schleicher C, Poremba C, Wolters H, Schäfer KL, Senninger N, Colombo-Benkmann M,. Gain of chromosome 8q: a potential prognostic marker in resectable adenocarcinoma of the pancreas? Ann Surg Oncol. 2007; 14: 1327-1335. (Pubitemid 46536800)
13. Weber RG, Pietsch T, von Schweinitz D, Lichter P,. Characterization of genomic alterations in hepatoblastomas. A role for gains on chromosomes 8q and 20 as predictors of poor outcome. Am J Pathol. 2000; 157: 571-578. (Pubitemid 30627562)
14. Klatte T, Pantuck AJ, Said JW, et al. Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. Clin Cancer Res. 2009; 15: 1162-1169.
15. Sobin LH, Gospodarowicz MK, Wittekind C, editors. Urological Tumours-Kidney. In: TNM Classification of Malignant Tumours. 7th edition. Oxford, UK: Wiley-Blackwell; 2009: 255-257.
16. Fuhrman SA, Lasky LC, Limas C,. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982; 6: 655-663. (Pubitemid 13234762)
17. Lam JS, Shvarts O, Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS,. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol. 2005; 174: 466-472. (Pubitemid 40981575)
18. Shaffer LG, Slovak ML, Campbell LJ, editors. ISCN 2009: An International System for Human Cytogenetic Nomenclature (2009). Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. Basel, Switzerland: Karger; 2009.
19. Beroukhim R, Brunet JP, Di Napoli A, et al. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res. 2009; 69: 4674-4681.
20. Gordan JD, Lal P, Dondeti VR, et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell. 2008; 14: 435-446.
21. Klatte T, Pantuck AJ,. Molecular biology of renal cortical tumors. Urol Clin North Am. 2008; 35: 573-580.
22. Keith B, Johnson RS, Simon MC,. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 2011; 12: 9-22.
23. Kozma L, Kiss I, Nagy A, Szakall S, Ember I,. Investigation of c-myc and K-ras amplification in renal clear cell adenocarcinoma. Cancer Lett. 1997; 111: 127-131. (Pubitemid 27068227)
24. Kinouchi T, Saiki S, Naoe T, et al. Correlation of c-myc expression with nuclear pleomorphism in human renal cell carcinoma. Cancer Res. 1989; 49: 3627-3630. (Pubitemid 19178187)
25. Lanigan D, McLean PA, Murphy DM, Donovan MG, Curran B, Leader M,. c-myc expression in renal carcinoma: correlation with clinical parameters. Br J Urol. 1993; 72: 143-147. (Pubitemid 23252588)
26. Yamaguchi S, Yoshihiro S, Matsuyama H, et al. The allelic loss of chromosome 3p25 with c-myc gain is related to the development of clear-cell renal cell carcinoma. Clin Genet. 2003; 63: 184-191. (Pubitemid 36949918)
27. Zhang QL, Luo CL, Wu XH, et al. HepaCAM induces G1 phase arrest and promotes c-Myc degradation in human renal cell carcinoma. J Cell Biochem. 2011; 112: 2910-2919.
28. Zisman A, Pantuck AJ, Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. 2002; 20: 4559-4566. (Pubitemid 35402959)
29. Klatte T, Seligson DB, LaRochelle J, et al. Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. Cancer Epidemiol Biomarkers Prev. 2009; 18: 894-900.
30. Finley DS, Pantuck AJ, Belldegrun AS,. Tumor biology and prognostic factors in renal cell carcinoma. Oncologist. 2011; 16 (suppl 2): 4-13.
31. Furge KA, Chen J, Koeman J, et al. Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma. Cancer Res. 2007; 67: 3171-3176. (Pubitemid 46724854)